On April 2, 2026, Lipocine Inc. (NASDAQ: LPCN) announced the topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154, an oral formulation of brexanolone, for the treatment of postpartum depression (PPD). The study, which included 90 patients, did not meet its primary endpoint of demonstrating a statistically significant reduction in the Hamilton Depression Rating Scale (HAM-D17) total score compared to placebo at hour 60. However, a post hoc analysis revealed that among participants with a history of psychiatric conditions, LPCN 1154 showed nominal statistically significant and clinically meaningful reductions in HAM-D scores as early as hour 12 and sustained through day 30. The overall population reported that LPCN 1154 was well tolerated, with no adverse events occurring in more than 5% of treated participants. The company plans to evaluate all available options going forward, including potential submissions for breakthrough therapy and fast track designations with the FDA. Despite the primary endpoint not being met, the results indicate a differentiated safety profile and potential for outpatient administration without the need for healthcare provider monitoring. Lipocine's ongoing commitment to developing innovative treatments for PPD remains strong, as they continue to engage with stakeholders to assess future pathways for LPCN 1154.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.